Answers are grounded in this paper and cite their sources.
The Ki-67 proliferation index is an important biomarker for evaluating glioma aggressiveness but is conventionally determined by postoperative histopathological examination. We developed and internally validated a non-invasive framework integrating multisequence magnetic resonance imaging (MRI) radiomics, deep learning (DL) features, and clinical variables for preoperative prediction of Ki-67 expression in gliomas. A total of 179 patients with pathologically confirmed primary glioma were retrospectively enrolled and randomly assigned to training ( n = 125) and internal validation ( n = 54) cohorts. Handcrafted radiomics features were extracted from intratumoral and multi-scale peritumoral regions on T1-weighted contrast-enhanced, T1FLAIR, and T2-weighted MRI, while high-level imaging features were generated using pre-trained convolutional neural networks. Selected imaging components were integrated with clinical variables to construct multimodal predictive models. The inclusion of peritumoral features showed potential value for improving radiomics-based prediction compared with intratumoral features alone. The multimodal integrated model achieved AUCs of 0.869 (95% CI, 0.803–0.934) and 0.849 (95% CI, 0.744–0.953) in the training and internal validation cohorts, respectively, showing a higher observed AUC than the conventional machine learning, DNN-based, and transformer-based models. The clinical model achieved an internal validation AUC of 0.853. These findings highlight the potential value of integrating multi-regional MRI features for preoperative Ki-67 prediction and provide a basis for further investigating the contribution of peritumoral imaging information to glioma characterization.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: